Antimicrobial therapeutics have extremely high societal value and investing in a strong R&D ecosystem and market offers an opportunity to...

The " UK Antimicrobial subscription model " is the world's first, and currently only, pull incentive for antimicrobial development. The...

Over the past several months, ARMoR has worked alongside the G7 Research Group at the University of Toronto to assess the compliance of...